Orphan Drug Designation
ODDFDA & Regulatory
Orphan Drug Designation (ODD) applies to therapies for rare diseases affecting fewer than 200,000 people in the U.S. It confers incentives including tax credits, fee waivers, and seven years of market exclusivity on approval.
Related terms
Learn more
Track Orphan Drug Designation across 1,000+ biotechs
BioSniper monitors FDA decisions, clinical trials, and catalysts in real time — with evidence-backed AI analysis.
Start Free